Peptide Sciences Research

Introduction

Peptides have become one of the most exciting frontiers in modern health, wellness, and biotechnology research. Unlike proteins, which are typically composed of long chains of amino acids, peptides are shorter sequences that can wield significant influence on the body’s physiological and biochemical processes. While many individuals may have heard of peptides like collagen peptides for skin health or creatine peptides for muscle performance, a new wave of advanced and highly specialized peptides is quickly garnering attention among researchers. One promising candidate is SLU-PP-332.

SLU-PP-332 is touted by some researchers as a potentially versatile agent, with studies hinting at its efficacy in various areas—ranging from supporting skin integrity to possibly contributing to muscle repair and inflammatory response modulation. But what exactly is SLU-PP-332, and how does it work? Most importantly, why should the public care about it?

SLU-PP-332 is a synthetic small molecule recognized as a potent but non-selective agonist of the estrogen-related receptor (ERR), displaying its strongest activity at ERRα with an EC50 of 98 nM. It has attracted attention in biomedical research for potential applications in metabolic health and exercise mimetics. Synthesized in the early 2000s at Saint Louis University School of Medicine—reflected by the “SLU” prefix—this compound represents a novel category of ERR modulators engineered to selectively engage ERR pathways without exhibiting estrogenic effects.

OS-01: Unlocking Potential Through AMPK Activation
OS-01 emerges as an innovative, pan-AMPK activator demonstrating broad therapeutic potential across metabolic regulation, cardiovascular health, kidney protection, aging, and pain management. With a unique mode of action distinct from traditional AMPK activators, OS-01 leverages cellular energy pathways to promote extensive health benefits without common side effects.

Introduction
Peptide OS-01 is a novel molecule making waves in skin science for its promising anti-aging benefits. It is a lab-designed peptide (also known as “Pep-14”) that targets fundamental cellular aging processes in the skin​. In skincare, peptides have gained renown as powerful active ingredients that can boost collagen production, stimulate cell activity, or calm inflammation​. Unlike traditional peptides that mostly signal superficial improvements (like enhanced moisture or collagen), OS-01 is uniquely positioned as a “senotherapeutic” peptide – one that helps manage senescent cells (often nicknamed “zombie cells”) in aging skin​. By addressing cellular senescence, OS-01 aims to strengthen skin from within and potentially even reverse some markers of skin aging​. This evidence-based research article will delve into OS-01’s scientifically validated skin benefits, explaining the research behind its development, how it works in the skin, and what makes it stand out among skincare innovations.

Introduction 

SLU-PP-332 is a synthetic agonist of the estrogen receptor-related receptors (ERRs), a group of nuclear receptors that regulate energy metabolism. By selectively activating these receptors, SLU-PP-332 enhances the body's natural aerobic exercise response, leading to amplified energy expenditure and accelerated fat metabolism. This compound mimics and intensifies physiological metabolic pathways typically triggered by exercise, making it a potential game-changer in metabolic health and fitness.

What is BPC-157?

BPC-157 is a partial sequence of body protection compound (BPC) found in human gastric juice. It is mostly used in research to accelerate healing of a variety of wounds including tendon-to-bone healing and healing of damaged ligaments. This peptide acts systematically in the digestive tract to combat leaky gut, IBS, gastrointestinal cramps, and Crohn's disease. In addition, BPC-157 can protect and prevent ulcers, and it can be used to protect the liver from toxic damage from alcohol, antibiotics, etc. This peptide has also been promising in promoting the healing of traumatic brain injury (TBI) according to research.